Current standards for diagnosing multiple sclerosis (MS) are based on the 2018 revision of McDonald criteria. They rely on MRI detection (or clinical demonstration) of demyelinating lesions in the CNS, which are distributed in space (DIS) and in time (DIT). It is also a requirement that any possible known disease that produces demyelinating lesions is ruled out before applying McDonald's criteria.Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria Thompson, Alan J et al. The Lancet Neurology, Volume 17, Issue 2, 162 - 173
This last requirement makes MS an ill-defined entity, whose borders change every time that a new disease is set apart. Some cases previously considered MS are now considered distinct conditions, like Neuromyelitis optica or antiMOG associated encephalomyelitis. Because of the requirement of distributed lesions, a single lesion (RIS) is not considered MS. For the same reason, the prodromal stage of MS (the unknown condition that causes the lesions) would not be considered as MS if it could be found.Flemmen, H. Ø. (2023). Socioeconomic factors in multiple sclerosis (Doctoral dissertation, University of Oslo). University of Oslo. pp. 21, 29, 45. Retrieved from https://www.duo.uio.no/bitstream/handle/10852/102551/1/PhD-Flemmen.pdf
Sometimes the diagnosis must be retrospective, relying on gradual worsening of neurological signs/symptoms, due to the lack of understanding of the pathogenicity driving disease progression. However, the only definite diagnosis of MS is post-mortem autopsy, where lesions typical of MS can be detected through histopathological techniques.
Overview Multiple sclerosis is typically diagnosed based on the presenting signs and symptoms, in combination with supporting medical imaging and laboratory testing. It can be difficult to confirm, especially early on, since the signs and symptoms may be similar to those of other medical problems.
The McDonald criteria, which focus on clinical, laboratory, and radiologic evidence of lesions at different times and in different areas, is the most commonly used method of diagnosis. They came in during 2001, and have since been revised several times.
Clinical data alone may be sufficient for a diagnosis of MS if an individual has had separate episodes of neurologic symptoms characteristic of the disease. In those who seek medical attention after only one attack, other testing is needed for the diagnosis. The most commonly used diagnostic tools are neuroimaging, analysis of cerebrospinal fluid and evoked potentials. Magnetic resonance imaging of the brain and spine may show areas of demyelination (lesions or plaques). Gadolinium can be administered intravenously as a contrast agent to highlight active plaques and, by elimination, demonstrate the existence of historical lesions not associated with symptoms at the moment of the evaluation. Testing of cerebrospinal fluid obtained from a lumbar puncture can provide evidence of chronic inflammation in the central nervous system. The cerebrospinal fluid is tested for oligoclonal bands of IgG on electrophoresis, which are inflammation markers found in 75–85% of people with MS. The nervous system in MS may respond less actively to stimulation of the optic nerve and sensory nerves due to demyelination of such pathways. These brain responses can be examined using visual- and sensory-evoked potentials.
History Previous diagnosis was by the Schumacher and Poser criteria. Some stated that the only definitive proof was an autopsy or biopsy where lesions typical of MS could be detected.
Trends towards earlier diagnosis
Prodromal or early phase Studies have found increased interactions with health services by people who were diagnosed with MS several years later. The range of symptoms included pain and fatigue. Studies continue on whether MS has a prodromal or early phase, and could possibly be diagnosed and treated much earlier.
DMT effectiveness A range of disease-modifying treatments (DMT) are available, to reduce the long-term progression of MS. Studies have indicated that early and aggressive use of DMTs is beneficial for long-term outcomes.
Diagnostic criteria
McDonald criteria
As of 2021, the McDonald criteria for MS are the most commonly used.
The 2017 McDonald criteria can be summarize in this table:
Clinical Presentation Additional Data Needed * 2 or more attacks (relapses) * 2 or more objective clinical lesions None; clinical evidence will suffice (additional evidence desirable but must be consistent with MS)* 2 or more attacks * 1 objective clinical lesion (as well as clear-cut historical evidence of a previous attack involving a lesion in a distinct anatomical location)None. * 2 or more attacks * 1 objective clinical lesion Dissemination in space, demonstrated by an additional clinical attack implication a different CNS site or by MRI. * 1 attack * 2 or more objective clinical lesionsDissemination in time, demonstrated by an additional clinical attack or by MRI OR
Demonstration of CSF-specific oligoclonal bands * 1 attack * 1 objective clinical lesion (monosymptomatic presentation)Dissemination in space demonstrated by an additional clinical attack implicating a different CNS site or by MRI.ANDDissemination in time demonstrated by an additional clinical attack or by MRI, OR Demonstration of CSF-specific oligoclonal bandsInsidious neurological progression suggestive of MS (primary progressive MS)One year of disease progression (retrospectively or prospectively determined) and Two of the following:
One or more T2-hyperintense lesions characteristic of multiple sclerosis in one or more of the following brain regions: periventricular, cortical or juxtacortical, or infratentorial Two or more T2-hyperintense lesions in the spinal cord Presence of CSF-specific oligoclonal bands
Okuda Criteria
These criteria, used mainly for research in MS, define what should be considered a Radiologically Isolated Syndrome (RIS). Some reports point to the possibility of predicting RIS to CIS conversion based on oligoclonal bands and neurofilament light chain.
Research into diagnostic techniques
Multiple sclerosis diagnosis can only be made when there is proof of lesions disseminated in time and in space. Therefore, when damage in the CNS is big enough to be seen. It would be desirable to make it faster.
The ideal diagnosis schema would be able to determine for any given subject, if he will develop MS, at any point in his life, and when. Nevertheless, not enough is currently known about the MS underlying conditions to achieve that.
In order to get as close as possible to the ideal diagnosis status, a lot of research into multiple sclerosis biomarkers is taking place currently.
Biomarkers in MS
An active field of research is looking for biomarkers for MS that could speed-up the diagnosis doing it more accurate at the same time. While most of them are still under research, there are some of them already well stablished:
oligoclonal bands: They present proteins that are in the CNS or in blood. Those that are in CNS but not in blood suggest a diagnosis of MS. MRZ reaction: A polyspecific antiviral immune response against the viruses of measles, rubella and zoster found in 1992. In some reports the MRZR showed a lower sensitivity than OCB (70% vs. 100%), but a higher specificity (69% vs. 92%) for MS. free light chains (FLC), specially the kappa-FLCs (kFLCs). Several authors have reported that the nephelometric and ELISA FLCs determination is comparable with OCBs as markers of IgG synthesis, and kFLCs behave even better than oligoclonal bands.
Differential diagnosis Several conditions can mimic MS. Given the unknown pathogenesis of MS, its differential diagnosis is based in exclusion of known conditions.Jarius, S., Paul, F., Aktas, O., Asgari, N., Dale, R. C., de Seze, J., Franciotta, D., Fujihara, K., Jacob, A., Kim, H. J., Kleiter, I., Kümpfel, T., Levy, M., Palace, J., Ruprecht, K., Saiz, A., Trebst, C., Weinshenker, B. G., & Wildemann, B. (2018). MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. Journal of neuroinflammation, 15(1), 134. https://doi.org/10.1186/s12974-018-1144-2
Very close diseases with similar symptoms are the whole "inflammatory demyelinating diseases spectrum", specially neuromyelitis optica and anti-MOG associated encephalomyelitis.Jarius, S., Paul, F., Aktas, O., Asgari, N., Dale, R. C., de Seze, J., Franciotta, D., Fujihara, K., Jacob, A., Kim, H. J., Kleiter, I., Kümpfel, T., Levy, M., Palace, J., Ruprecht, K., Saiz, A., Trebst, C., Weinshenker, B. G., & Wildemann, B. (2018). MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. Journal of neuroinflammation, 15(1), 134. https://doi.org/10.1186/s12974-018-1144-2
Outside this spectrum, another important mimic is neuroborreliosis. A Borrelia-specific IgG index exists, and testing for it could make the differential diagnosis.
Clinical courses
Several phenotypes (commonly named types), or patterns of progression, have been described. Phenotypes use the past course of the disease in an attempt to predict the future course. They are important not only for prognosis but also for treatment decisions. In 1996, the United States National Multiple Sclerosis Society described four clinical courses.
The original structure approved in 1996, sometimes still used, was:
relapsing-remitting secondary progressive (SPMS) primary progressive (PPMS) progressive relapsing.
This set of courses was reviewed by an international panel in 2013, adding clinically isolated syndrome (CIS) and radiologically isolated syndrome (RIS) as phenotypes, and finally removing the "progressive relapsing" phenotype. They also added modificators for the clinical courses based on a pair of characteristics: Active/non-active and with/without progression.
The four currently accepted courses or stages are:
Clinically isolated syndrome (CIS) Relapsing-remitting MS (RRMS) Primary progressive MS (PPMS) Secondary progressive MS (SPMS)
Relapsing-remitting The relapsing-remitting subtype is characterized by unpredictable relapses followed by periods of months to years of relative quiet (remission) with no new signs of disease activity. Deficits that occur during attacks may either resolve or leave problems, the latter in about 40% of attacks and being more common the longer a person has had the disease. This describes the initial course of 80% of individuals with MS. When deficits always resolve between attacks, this is sometimes referred to as benign MS, although people will still build up some degree of disability in the long term. On the other hand, the term malignant multiple sclerosis is used to describe people with MS having reached significant level of disability in a short period. The relapsing-remitting subtype usually begins with a clinically isolated syndrome (CIS). In CIS, a person has an attack suggestive of demyelination, but does not fulfill the criteria for multiple sclerosis. 30 to 70% of persons experiencing CIS later develop MS.
Secondary progressive
Secondary progressive MS occurs in around 65% of those with initial relapsing-remitting MS, who eventually have progressive neurologic decline between acute attacks without any definite periods of remission. Occasional relapses and minor remissions may appear. The most common length of time between disease onset and conversion from relapsing-remitting to secondary progressive MS is 19 years.
Primary progressive